Clinical Trial Update: Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating amifostine with or without epoetin alfa in patients with myelodysplastic syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Syndromes

Drugs mentioned

• Amifostine (amifostine)
• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Anemia, Myelodysplastic Syndromes | Phase 2 | Status: UNKNOWN